Drug
Aggrenox
Aggrenox: highest development phase Phase 3, developed by Boehringer Ingelheim. 1 trial record tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Boehringer Ingelheim
Trials
| Drug | Phase | Indication |
|---|---|---|
| Aggrenox capsule NCT00311402 | Phase 3 | Cerebrovascular Accident |
Latest
No recent events.
Follow Aggrenox on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.